Physician profile
Swaraj Singh
NPI 1851599682
$15,704.03
in general payments reported to CMS, 2019-2025
62 companies · $3,485 in 2025
The $3,485 reported for 2025 was more than what 85% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,362 · 2021: $990 · 2022: $1,078 · 2023: $2,742 · 2024: $4,259 · 2025: $3,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,486.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,911.14 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Ucb, INC. | $1,396.79 | 2019-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,141.13 | 2019-2025 | |
| Genentech USA, INC. | $1,049.24 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Acadia Pharmaceuticals INC | $985.82 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $760.16 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $754.28 | 2019-2025 | Vumerity, Tysabri |
| Amneal Pharmaceuticals LLC | $677.73 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Alexion Pharmaceuticals, INC. | $612.36 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $561.04 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $481.27 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $471.57 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Emd Serono, INC. | $462.22 | 2019-2023 | Mavenclad |
| Eisai INC. | $458.23 | 2019-2025 | |
| Pfizer INC. | $433.91 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swaraj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.